Skip to main content

What the FDA labels say about taking them together

Ibandronate and ranitidine

Ibandronate's FDA label of March 18, 2026 names ranitidine in its drug interactions section; the ranitidine label PlainMeds reads does not name ibandronate. The ibandronate label: “H 2 Blockers In healthy volunteers, co-administration with ranitidine resulted in a 20% increased bioavailability of ibandronate, which was not considered to be clinically relevant.”

Check it at the source: the ibandronate FDA label on DailyMed (effective March 18, 2026, Aurobindo Pharma Limited); the ranitidine FDA label on DailyMed (effective May 1, 2026, Amneal Pharmaceuticals of New York LLC).

What does the ibandronate label say about ranitidine?

Ibandronate label, drug interactions

H 2 Blockers In healthy volunteers, co-administration with ranitidine resulted in a 20% increased bioavailability of ibandronate, which was not considered to be clinically relevant (see CLINICAL PHARMACOLOGY [12.3] ).

Source: FDA drug label (Ibandronate Sodium), Aurobindo Pharma Limited, effective March 18, 2026 (SPL set 86c0b4ae-5e38-4efe-88af-50ac560e294f), via openFDA; the full label on DailyMed

What does the ranitidine label say about ibandronate?

Ranitidine's label (effective May 1, 2026) does not name ibandronate in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Ranitidine), Amneal Pharmaceuticals of New York LLC, effective May 1, 2026 (SPL set b38a3332-5c54-453f-aeb7-070f830955c2), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

9Ibandronate generic labelers
8Ranitidine generic labelers
IbandronateRanitidine
Labeled forOsteoporosisAcid reflux and ulcers
Boxed warningNoNo
Pharmacy cost (NADAC)$2.68 per tablet 150 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?